CAJ | 학술논문

目的探讨艾迪注射液辅助化疗对中晚期非小细胞肺癌(NSCLC)患者外周血CD+4CDhi25CDlow127调节性T(Treg)细胞表达的影响.方法 60例NSCLC患者随机分为化疗加艾迪注射液组(观察组)和单纯化疗组(对照组),采用流式细胞术(FCM)和酶联免疫吸附法(ELISA)分别于化疗前后检测外周血中CD+4CDhi25CDlow127Treg细胞和血清TGF-β 1、IL-10水平,同期选取20名健康体检者为健康对照组.结果 NSCLC患者外周血中CD+4CDhi25CDlow127Treg细胞占CD+4淋巴细胞的比例为(5.77±1.50)%,与健康对照组(3.84±0.96)%相比差异有统计学意义(P=0.000);血清中IL-10和TGF-β 1表达水平[(24.09±6.74)、(197.76±43.76)ng/ml]明显高于健康对照[(19.39±5.73)、(141.13±32.17)ng/ml](P=0.006,P=0.002).对照组化疗后CD+4CDhi25CDlow127Treg细胞水平显著降低(P=0.048),细胞因子IL-10、TGF-β1的表达水平[(22.25±6.79)、(184.85±49.11)ng/ml]与化疗前[(24.37±8.10)、(197.16±44.57)ng/ml]相比差异无统计学意义(P=0.276,P=0.314).观察组化疗后CD+4CDhi25CDlow127Treg细胞和细胞因子IL-10、TGF-β1表达水平[(4.36±1.19)%,(20.16±4.73)、(165.42±39.57)ng/ml]与化疗前[(5.78±1.50)ng/ml,(23.81±5.15)、(198.35±43.68)ng/ml]相比降低,差异有统计学意义(P=0.000,P=0.006,P=0.003).结论中晚期NSCLC患者外周血中Treg细胞表达水平增高,艾迪注射液配合化疗可以降低NSCLC患者的Treg细胞水平,改善机体免疫状态.
목적 탐토애적주사액보조화료대중만기비소세포폐암(NSCLC)환자외주혈CD+4CDhi25CDlow127조절성T(Treg)세포표체적영향.방법 60례NSCLC환자수궤분위화료가애적주사액조(관찰조)화단순화료조(대조조),채용류식세포술(FCM)화매련면역흡부법(ELISA)분별우화료전후검측외주혈중CD+4CDhi25CDlow127Treg세포화혈청TGF-β 1、IL-10수평,동기선취20명건강체검자위건강대조조.결과 NSCLC환자외주혈중CD+4CDhi25CDlow127Treg세포점CD+4림파세포적비례위(5.77±1.50)%,여건강대조조(3.84±0.96)%상비차이유통계학의의(P=0.000);혈청중IL-10화TGF-β 1표체수평[(24.09±6.74)、(197.76±43.76)ng/ml]명현고우건강대조[(19.39±5.73)、(141.13±32.17)ng/ml](P=0.006,P=0.002).대조조화료후CD+4CDhi25CDlow127Treg세포수평현저강저(P=0.048),세포인자IL-10、TGF-β1적표체수평[(22.25±6.79)、(184.85±49.11)ng/ml]여화료전[(24.37±8.10)、(197.16±44.57)ng/ml]상비차이무통계학의의(P=0.276,P=0.314).관찰조화료후CD+4CDhi25CDlow127Treg세포화세포인자IL-10、TGF-β1표체수평[(4.36±1.19)%,(20.16±4.73)、(165.42±39.57)ng/ml]여화료전[(5.78±1.50)ng/ml,(23.81±5.15)、(198.35±43.68)ng/ml]상비강저,차이유통계학의의(P=0.000,P=0.006,P=0.003).결론 중만기NSCLC환자외주혈중Treg세포표체수평증고,애적주사액배합화료가이강저NSCLC환자적Treg세포수평,개선궤체면역상태.
Objective To investigate the effect of Aidi injection combined with chemotherapy on CD+4CDhi25CDlow127regulatory T (Treg) cells in peripheral blood of advanced non-small-cell lung cancer (NSCLC).Methods Sixty patients with advanced NSCLC were randomly divided into the study group (treated with Aidi injection combined with chemotherapy) and the control group (treated with chemotherapy).The levels of CD+4CDhi25CDlow127Treg cells were detected by flow cytometry (FCM), and TGF-β1 and IL-10 levels were determined by enzyme linked immunosorbent assay (ELISA) before and after chemotherapy. A group consisted of 20 healthy persons was set up meanwhile.Results There was a significantly higher percentage of CD+4CDhi25CDlow127Treg cells in patients with NSCLC (5.77±1.50) % than that(3.84±0.96) % of healthy volunteers (P=0.000).The IL-10 and TGF-β1 levels[(24.09±6.74), (197.76±43.76) ng/ml]in the serum of patients with NSCLC were also significantly higher than that[(19.39±5.73), (141.13±32.17) ng/ml]of healthy volunteers (P =0.006,P =0.002). In control group, levels of CD+4CDhi25CDlow127 Treg cells were obviously lower than that before chemotherapy (P =0.048).Levels of TGF-β1 and IL-10[(22.25±6.79), (184.85±49.11) ng/ml]were slightly decreased, which showed no significant difference contrast to pretherapy[(24.37±8.10), (197.16±44.57) ng/ml](P =0.276, P =0.314).In study group, levels of CD+4CDhi25CDlow127Treg cells and TGF-β1, IL-10[(4.36±1.19) %,(20.16±4.73), (165.42±39.57) ng/ml]were obviously lower than that before chemotherapy[(5.78±1.50) %,(23.81±5.15), (198.35±43.68) ng/ml](P=0.000, P=0.003, P =0.006).Conclusion The CD+4CDhi25CDlow127 Treg cells in the peripheral blood of advanced NSCLC patients is significantly increased. Aidi injection combined with chemotherapy can obviously reduce the level of CD+4CDhi25CDlow127 Treg cells in patients with advanced NSCLC, and the combined therapy could improve the immune function of patients.